Multimorbidade inflamatória: sobreposição de doenças reumatológicas com insuficiência cardíaca
DOI:
https://doi.org/10.34119/bjhrv9n1-189Keywords:
inflamação sistêmica, autoimunidade, risco cardiovascularAbstract
A multimorbidade inflamatória, caracterizada pela coexistência de doenças reumatológicas autoimunes e insuficiência cardíaca, configura um importante desafio clínico e de saúde pública. Condições como artrite reumatoide, lúpus eritematoso sistêmico, psoríase/artrite psoriásica, síndrome de Sjögren e vasculites compartilham a inflamação sistêmica crônica como elo fisiopatológico central, promovendo disfunção endotelial, remodelamento cardíaco adverso e aumento do risco cardiovascular, independentemente dos fatores de risco tradicionais. Evidências apontam maior incidência de insuficiência cardíaca, especialmente com fração de ejeção preservada, além de maior morbimortalidade e taxas de hospitalização nesses pacientes. Trata-se de uma revisão integrativa da literatura, realizada na base de dados PubMed, com seleção de estudos publicados nos últimos dez anos, que abordaram a associação entre doenças reumatológicas inflamatórias, insuficiência cardíaca e conflitos terapêuticos. Foram incluídos estudos observacionais, ensaios clínicos e relatos de caso, analisados de forma descritiva e crítica. Os resultados evidenciam que a sobreposição com comorbidades cardiovasculares e renais impõe desafios significativos ao manejo, especialmente quanto ao uso de corticosteroides, anti-inflamatórios não esteroides e terapias imunobiológicas. Conclui-se que o reconhecimento precoce dessa multimorbidade e a integração entre reumatologia e cardiologia são fundamentais para o manejo individualizado, redução de complicações e melhoria do prognóstico clínico.
References
ALI, D. et al. Rise and fall of the eosinophils in heart failure: a rare but important phenomenon seen with cardiomyopathy. BMJ Case Reports, v. 2018, p. bcr-2017, 7 maio 2018.
ALFRAJI, N. et al. Nonischemic Dilated Cardiomyopathy in Untreated Long-Term Psoriasis: A Newly Recognized Association: A Case Report with Mini Review. American Journal of Case Reports, v. 22, 24 fev. 2021.
AMELOTTI, N. et al. What’s behind your eosinophilic myocarditis? A case of Churg–Strauss syndrome diagnosed during acute heart failure. ESC Heart Failure, v. 10, n. 1, p. 709–715, 19 out. 2022.
BANIAAMAM, M. et al. Clinical improvement of cardiac function in a patient with systemic lupus erythematosus and heart failure with preserved ejection fraction treated with belimumab. BMJ Case Reports, v. 14, n. 1, p. e237549, Autumn 2021.
BUTT, J. H. et al. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout. v. 8, n. 4, p. 386–386, 1 abr. 2023.
CASTRO DE OLIVEIRA FIGUEIRÔA, M. D. L. et al. Acute heart failure due to myocarditis in Takayasu’s arteritis. Reumatismo, v. 76, n. 4, p. 10.4081/reumatismo.2024.1681, Winter 2024.
CHEN, S. K. et al. Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. Seminars in Arthritis and Rheumatism, v. 49, n. 3, p. 389–395, dez. 2019.
FEHER, A. et al. Association Between Impaired Myocardial Flow Reserve on 82 Rubidium Positron Emission Tomography Imaging and Adverse Events in Patients With Autoimmune Rheumatic Disease. Circulation: Cardiovascular Imaging, v. 14, n. 9, 1 set. 2021.
GORDON, J. B. et al. The Spectrum of Cardiovascular Lesions Requiring Intervention in Adults After Kawasaki Disease. JACC: Cardiovascular Interventions, v. 9, n. 7, p. 687–696, abr. 2016.
HARROLD, L. R. et al. Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry. The Journal of Rheumatology, v. 47, n. 7, p. 959–967, 1 ago. 2019.
HAWKINS, A. M.; JESUTHASAN, L. S. B.; VARDESH, D. L. Case of severe acute lupus myocarditis and multiple-organ failure. BMJ Case Reports, v. 2018, p. bcr2018225085, 2018.
HE, V. Y. F. et al. Long-Term Outcomes From Acute Rheumatic Fever and Rheumatic Heart Disease. Circulation, v. 134, n. 3, p. 222–232, 19 jul. 2016.
KARPOUZAS, G. A. et al. Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High‐Risk Lesions. Arthritis & Rheumatology, v. 72, n. 9, p. 1467–1475, 7 ago. 2020.
KHALID, U. et al. Incident Heart Failure in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, v. 7, n. 2, 19 jan. 2018.
LIN, Y.-T. et al. Molecular Hydrogen Therapy in Sjögren’s Syndrome With Pulmonary Arterial Hypertension and Right-sided Heart Failure: A Case Report of Improved Immune Markers Including Treg, B Cells and Plasma Cell. In Vivo (Athens, Greece), v. 38, n. 6, p. 3117–3124, 2024.
LIN, Y.-T. et al. Molecular Hydrogen as an Adjuvant Therapy in Severe Lupus Serositis With Heart Failure: A Case Report on Immune Modulation and Fatigue Reduction. In Vivo (Athens, Greece), v. 39, n. 2, p. 1200–1206, 2025.
OZGUR, S. S. et al. A Case of Cardiac Tamponade With Biventricular Heart Failure in the Setting of Systemic Lupus Erythematosus. Journal of Investigative Medicine High Impact Case Reports, v. 12, p. 23247096241286379, 2024.
RÁCZ, Á. O. et al. Heart failure caused by Takayasu’s arteritis in the time of COVID‐19: a case report. ESC Heart Failure, 9 jul. 2022.
RIVERA, F. B. et al. Takayasu’s arteritis with giant left ventricular pseudoaneurysm presenting as heart failure. BMJ Case Reports, v. 14, n. 1, p. e237700, nov. 2021.
ROSER SOLANS-LAQUÉ et al. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides. Medicine, v. 96, n. 8, p. e6083–e6083, 1 fev. 2017.
SOTIRIA LIORI et al. Churg–Strauss syndrome‐associated heart failure and left ventricular thrombosis. ESC Heart Failure, v. 10, n. 3, p. 2107–2112, 25 mar. 2023.
SUN, G. et al. Long‐term risk of heart failure and other adverse cardiovascular outcomes in primary Sjögren’s syndrome. Journal of Internal Medicine, v. 293, n. 4, p. 457–469, 11 dez. 2022.
WU, J. et al. The necessity for prompt identification of Sjögren syndrome in instances of unexplained heart failure: A case report. Medicine, v. 104, n. 20, p. e42451, 16 maio 2025.
YAMAZAKI, O. et al. Effective Management of Hypertensive Emergencies with Aliskiren Treatment in a Patient before and after Introducing Hemodialysis Secondary to Scleroderma Renal Crisis-like Condition under Corticosteroid Treatment for Sjögren Syndrome-associated Multiple Mononeuropathy. Internal Medicine (Tokyo, Japan), v. 63, n. 16, p. 2301–2306, Autumn 2024.
ZHAO, S. S. et al. Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. Rheumatology, v. 60, n. 7, p. 3189–3198, 17 dez. 2020.
